Christian Marsolais

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.

Corrigendum: Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.

Journal: Frontiers in immunology

Published: February 21, 2024

Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.

Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.

Journal: Frontiers in immunology

Published: December 14, 2023

The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells.

The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells.

Journal: Pharmaceutics

Published: August 12, 2022

Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.

Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.

Journal: AIDS (London, England)

Published: March 09, 2022

The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers.

The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers.

Journal: Cancers

Published: February 09, 2022

New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells.

New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells.

Journal: Frontiers in oncology

Published: August 18, 2021

TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.

TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.

Journal: Cancer science

Published: May 04, 2021

Tesamorelin improves fat quality independent of changes in fat quantity.

Tesamorelin improves fat quality independent of changes in fat quantity.

Journal: AIDS (London, England)

Published: March 23, 2021

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Journal: The Journal of frailty & aging

Published: June 26, 2019

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.

Journal: The New England journal of medicine

Published: August 16, 2018

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

Journal: AIDS (London, England)

Published: August 24, 2017

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 13, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026